Vaccination issues in patients with inflammatory bowel disease receiving immunosuppression

Gastroenterology and Hepatology

Volumn 8, Issue 8, 2012, Pages 504-512

  Dezfoli, Seper ^a   Melmed, Gil Y ^a,b  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunization; Infection; Inflammatory bowel disease; Pertussis; Pneumococcal vaccine; Vaccination

Indexed keywords

ANTHRAX VACCINE; AZATHIOPRINE; BCG VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; SMALLPOX VACCINE; TETANUS TOXOID; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

CONDYLOMA ACUMINATUM; DRUG CONTRAINDICATION; ENTERITIS; HEPATITIS A; HEPATITIS B; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INFLUENZA; MENINGOCOCCOSIS; PERTUSSIS; PNEUMOCOCCAL INFECTION; REVIEW; TETANUS; VACCINATION;

EID: 84866851337     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Melmed G, Ippoliti A, Papadakis K, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834-1840. (Pubitemid 44166594)
2. Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol. 2003;26:19-22. (Pubitemid 36168871)
3. Toruner M, Loftus E Jr, Harmsen W, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936. (Pubitemid 351451967)
4. Viget N, Vernier-Massouille G, Salmon-Ceron D, et al. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut. 2008;57:549-558. (Pubitemid 351442541)
5. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003;62:686-687. (Pubitemid 36760576)
6. Deutsch DE, Olson AD, Kraker S, et al. Overwhelming varicella pneumonia in a patient with Crohn's disease treated with 6-mercaptopurine. J Pediatr Gastroenterol Nutr. 1995;20:351-353.
7. Lemyze M, Tavernier JY, Chevalon B, et al. Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease. Rev Mal Respir. 2003;20:773-776. (Pubitemid 37429426)
8. Foster K, Devitt N, Gallagher P, et al. Overwhelming pneumococcal septicaemia in a patient with ulcerative colitis and splenic atrophy. Gut. 1982;23:630-632. (Pubitemid 12081118)
9. Gupta G, Lautenbach E, Lewis J. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:1483-1490. (Pubitemid 44880029)
10. Loras C, Gisbert J, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut. 2010;59:1340-1346.
11. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-64.
12. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep. 1993;42(RR-4):1-18.
13. Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677-692. (Pubitemid 39276481)
14. Melmed G. Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Dis. 2009;15:1410-1416.
15. Thompson W, Shay D, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
16. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60:1128-1132.
17. Agarwal N, Ollington K, Kaneshiro M, et al. Are immunosuppressive medications associated with decreased responses to routine immunizations? A systematic review. Vaccine. 2012;30:1413-1424.
18. deBruyn JC, Hilsden R, Fonseca K, et al. Immunogenicity and safety of influenza vaccination in children with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:25-33.
19. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104:444-453.
20. Cullen G, Bader C, Korzenik JR, et al. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut. 2012;61:385-391.
21. Rahier JF, Papay P, Salleron J, et al. H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut. 2011;60:456-462.
22. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 2011;60:13-15.
23. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte- and platelet-derived substances during normal antitetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36:265-269. (Pubitemid 32234575)
24. Dotan I, Werner L, Vigodman S, et al. Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines. Inflamm Bowel Dis. 2012;18:261-268.
25. Dezfoli S, Horton H, Brer D, et al. Immunomodulators, but not anti-TNF monotherapy, impair pertussis and tetanus booster vaccine responses in adults with inflammatory bowel disease (IBD). Presented at Digestive Disease Week; May 19-22, 2012; San Diego, California. Abstract Su2081.
26. California Department of Public Health. Pertussis Report. Jan 2012.
27. Centers for Disease Control. Update: pneumococcal polysaccharide vaccine usage - United States. MMWR Morb Mortal Wkly Rep. 1984;33:273-276, 281.
28. Williams WW, Hickson MA, Kane MA, et al. Immunization policies and vaccine coverage among adults: the risk for missed opportunities. Ann Intern Med. 1988;108:616-625.
29. Stool SE, Field MJ. The impact of otitis media. Pediatr Infect Dis J. 1989;8(suppl):S11-S14. (Pubitemid 19044087)
30. Jernigan DB, Cetron MS, Breiman RF. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP): a strategy from the DRSP Working Group. JAMA. 1996;275:206-209. (Pubitemid 26028561)
31. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia, PA: WB Saunders; 1994:517-563.
32. Gardner P, Schaffner W. Immunization of adults. N Engl J Med. 1993;328:1252-1258.
33. Robbins JB, Austrian R, Lee CJ, et al. Considerations for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis. 1983;148:1136-1159. (Pubitemid 14206325)
34. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA. 1993;270:1826-1831. (Pubitemid 23301436)
35. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine. J Infect Dis. 1995;171;885-889.
36. Center for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997;46(RR-8):1-24.
37. Melmed GY, Frenck R, Barolet-Garcia C, et al. TNF blockers and immunomodulators impair antibody responses to pneumococcal polysaccharide vaccine (PPV) in patients with inflammatory bowel disease (IBD). Gastroenterology. 2008;134(4 suppl 1):A68.
38. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18:1042-1047.
39. Koutsky LA, Kiviat NB. Genital human papillomavirus. In: Holmes KK, Sparling PF, Mardh PA, et al, eds. Sexually Transmitted Diseases. New York, NY: McGraw-Hill; 1999:347-359.
40. Cervical cancer. NIH Consens Statement. 1996;14:1-38.
41. World Health Organization. Human papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 2007;90:1-689.
42. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527. (Pubitemid 36159887)
43. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-19. (Pubitemid 29406813)
44. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer - burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;31:3-13.
45. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204. (Pubitemid 40450709)
46. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030-3044.
47. Centers for Disease Control and Prevention. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:626-629.
48. Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2010;59:630-632.
49. Lu Y, Ashworth L, Bousvaros A, et al. Immune response to human papillomavirus vaccine (gardisil) in girls and young women with inflammatory bowel disease. Presented at Digestive Disease Week; May 7-10, 2011; Chicago, Illinois. Abstract 990.
50. Seksik P, Cosnes J, Sokol H, et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther. 2009;29:1106-1113.
51. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12:6167-6171. (Pubitemid 44688166)
52. Venkatesan T, Beaulieu DB, Ferrer V, et al. Abnormal PAP smears, cervical dysplasia and immunomodulator therapy in women with inflammatory bowel disease (IBD). Gastroenterology. 2006;130(4 suppl 2):A3.
53. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008;103:631-636. (Pubitemid 351405963)
54. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136:451-458.
55. Lees CW, Critchley J, Chee N, et al. Lack of association between cervical dysplasia and IBD: a large case-control study. Inflamm Bowel Dis. 2009;15:1621-1629.
56. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:72-76.
57. Workowski KA, Berman S; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
58. Radzikowski A, Banaszkiewicz A, Łazowska-Przeorek I, et al. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1117-1124.
59. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut. 2004;53:1363-1365. (Pubitemid 39120128)
60. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int. 2008;28:718-720.
61. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol. 2006;12:974-976.
62. Vida Pérez L, Gómez Camacho F, García Sánchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331-335.
63. Nyström J, Cardell K, Björnsdottir TB, et al. Improved cell mediated immune responses after successful re-vaccination of non-responders to the hepatitis B virus surface antigen (HBsAg) vaccine using the combined hepatitis A and B vaccine. Vaccine. 2008;26:5967-5972.
64. Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1996;45:1-36.
65. Lichtenstein G, Feagan B, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
66. Leung V, Nguyen M, Bush T. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol. 2004;99:2503-2504. (Pubitemid 40039388)
67. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1-40.
68. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105:1231-1238.
69. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
70. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-15):1-48.
71. Ihara T, Kamiya H, Torigoe S, Sakurai M, Takahashi M. Viremic phase in a leukemic child after live varicella vaccination. Pediatrics. 1992;89:147-149.
72. Cullen G, Baden RP, Cheifetz AS. Varicella zoster virus infection in inflammatory bowel disease. Inflamm Bowel Dis. 2012 Mar 20. Epub ahead of print.
73. Lu Y, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. J Pediatr Gastroenterol Nutr. 2010;50:562-565.
74. Staples JE, Gershman M, Fischer M; Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59(RR-7):1-27.
75. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L. Measles, mumps, and rubella - vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1998;47(RR-8):1-57.
76. Kotton CN. Vaccines and inflammatory bowel disease. Dig Dis. 2010;28:525-535.
77. Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-605.
78. Jong EC, Freedman DO. Immunocompromised travelers. Centers for Disease Control and Prevention. wwwnc.cdc.gov/travel/yellowbook/2012/chapter-8-advising- travelers-with-specific-needs/immunocompromised-travelers.htm.